Neuberger Berman Group’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.2M Sell
48,841
-3,035
-6% -$1.05M 0.01% 736
2026
Q2
$19.3M Buy
51,876
+18,792
+57% +$5.61M 0.01% 722
2026
Q1
$8.55M Buy
33,084
+32,051
+3,103% +$8.53M 0.01% 855
2025
Q4
$255K Buy
+1,033
New +$217K ﹤0.01% 1875
2021
Q4
– Sell
-45,246
Closed -$2.35M – 1927
2021
Q3
$2.35M Buy
45,246
+583
+1% +$34.5K ﹤0.01% 1128
2021
Q2
$3.03M Buy
44,663
+603
+1% +$42.1K ﹤0.01% 1085
2021
Q1
$3.39M Sell
44,060
-6,940
-14% -$505K ﹤0.01% 1040
2020
Q4
$3.06M Hold
51,000
– – ﹤0.01% 1028
2020
Q3
$2.2M Buy
51,000
+8,000
+19% +$347K ﹤0.01% 1047
2020
Q2
$1.78M Buy
43,000
+18,000
+72% +$866K ﹤0.01% 1025
2020
Q1
$1.08M Sell
25,000
-15,600
-38% -$816K ﹤0.01% 1081
2019
Q4
$2.25M Hold
40,600
– – ﹤0.01% 1009
2019
Q3
$1.41M Buy
40,600
+24,800
+157% +$1.11M ﹤0.01% 1078
2019
Q2
$636K Buy
15,800
+6,300
+66% +$206K ﹤0.01% 1244
2019
Q1
$313K Buy
+9,500
New +$224K ﹤0.01% 1356

Other funds holding KRYS

Neuberger Berman Group's KRYS Position: Q3 2026 in Review

Neuberger Berman Group reduced its Krystal Biotech (KRYS) stake by 5.9% in Q3 2026, selling an estimated $1.05M and leaving 48,841 shares worth $16.2M. The position accounts for 0.01% of the portfolio, ranked #736.

Neuberger Berman Group first reported a position in KRYS in Q1 2019 and has held it in 15 quarters since. The position peaked at $19.3M in Q2 2026. 442 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Neuberger Berman Group held 48,841 shares of Krystal Biotech worth $16.2M as of Q3 2026.
  • Neuberger Berman Group sold 3,035 Krystal Biotech shares in Q3 2026, an estimated $1.05M.
  • Krystal Biotech made up 0.01% of Neuberger Berman Group's portfolio in Q3 2026, its #736 holding.
  • Neuberger Berman Group first reported a position in Krystal Biotech in Q1 2019 and has held it in 15 quarters since.
  • Neuberger Berman Group's Krystal Biotech position peaked at $19.3M in Q2 2026.
  • 442 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Neuberger Berman Group's 13F filing for Q3 2026, filed 13 Nov 2026.